# Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

> **NCT04691622** · PHASE1 · RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 48 (estimated)

## Conditions studied

- Viral Infection
- Hematopoietic Stem Cell Transplantation (HSCT)
- Primary Immunodeficiency Disorders (PID)

## Interventions

- **BIOLOGICAL:** Norovirus -specific T-cell (NST) therapy

## Key facts

- **NCT ID:** NCT04691622
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-17
- **Primary completion:** 2028-08-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691622, "Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04691622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*